Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for MDGL

Stock NameMadrigal Pharmaceuticals Inc
TickerMDGL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5588681057
LEI549300CHIMT2EUSNJB60

Show aggregate MDGL holdings

News associated with MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $483.38 Consensus Target Price from Brokerages
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […] - 2025-09-17 02:42:46
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and BioNxt Solutions (OTCMKTS:BNXTF)
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Madrigal Pharmaceuticals and BioNxt […] - 2025-08-28 04:46:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-08-20 03:12:44
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Insider Selling
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $369.84, but opened at $354.56. Madrigal Pharmaceuticals shares last traded at $364.21, with a volume of 83,865 shares changing hands. Specifically, General Counsel Shannon T. Kelley sold […] - 2025-08-20 02:17:00
Stocks Mixed Before Trump-Zelenskiy Meeting and Retailer Earnings
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.09%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September... - 2025-08-18 14:26:35
Stocks Slightly Lower on Concern Over Progress to End Russian-Ukrainian War
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.17%. September E-mini S&P futures (ESU25 ) are down -0.06%, and September... - 2025-08-18 12:43:44
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $3,652,000.00 in Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Kenneth Bate sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director owned 2,627 shares of the company’s stock, […] - 2025-08-18 05:18:50
Cetera Investment Advisers Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Cetera Investment Advisers reduced its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,832 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Cetera Investment Advisers’ holdings in Madrigal Pharmaceuticals were worth $938,000 as of its […] - 2025-08-13 04:49:04
1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Blair William & Co. IL
Blair William & Co. IL bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $332,000. Other hedge funds also […] - 2025-08-12 05:00:47
Zurcher Kantonalbank Zurich Cantonalbank Sells 291 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Zurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 2,138 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Madrigal Pharmaceuticals were worth $708,000 as of […] - 2025-08-07 04:26:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up on Strong Earnings
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $312.11, but opened at $350.00. Madrigal Pharmaceuticals shares last traded at $330.70, with a volume of 156,412 shares traded. The biopharmaceutical company reported ($1.90) […] - 2025-08-07 02:12:57
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 1,000 Shares of Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Rebecca Taub sold 1,000 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the transaction, the director owned 461,044 shares in the company, valued at $161,365,400. […] - 2025-07-24 05:51:01
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $490,042.00 in Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 1,400 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 […] - 2025-07-24 05:50:51
New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
New York State Common Retirement Fund lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 […] - 2025-07-18 06:22:45
Mutual of America Capital Management LLC Boosts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Mutual of America Capital Management LLC grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,263 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during […] - 2025-07-18 05:49:00
D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
D.A. Davidson & CO. grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 203.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,458 shares during the period. D.A. Davidson & CO.’s […] - 2025-07-10 05:25:03
First Horizon Advisors Inc. Grows Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 38.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 157 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the period. First Horizon Advisors Inc.’s […] - 2025-07-08 05:08:55
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $420.63 Consensus Price Target from Analysts
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The […] - 2025-07-04 02:40:48
QRG Capital Management Inc. Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 726 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. Other institutional investors also recently bought and sold shares of the company. […] - 2025-06-24 04:42:49
Head-To-Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Larimar Therapeutics (NASDAQ:LRMR)
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Larimar Therapeutics and Madrigal […] - 2025-06-12 03:09:35
Wellington Management Group LLP Has $2.52 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Wellington Management Group LLP lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,172 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. Wellington Management Group LLP’s holdings […] - 2025-06-06 05:04:52
Analysts Anticipate 12% Upside For The Holdings of AVLC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:37:18
Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) and Adicet Bio (NASDAQ:ACET)
Adicet Bio (NASDAQ:ACET – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Volatility & Risk Adicet Bio has a beta […] - 2025-05-21 03:01:02
MDGL Crosses Below Key Moving Average Level
In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal Pharmaceuticals Inc shares are currently trading down about 2.5% on the day. The chart bel - 2025-05-14 12:56:35
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 06:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 04:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC
Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 05:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 05:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC
Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 05:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 04:20:54

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc MDGL holdings

DateNumber of MDGL Shares HeldBase Market Value of MDGL SharesLocal Market Value of MDGL SharesChange in MDGL Shares HeldChange in MDGL Base ValueCurrent Price per MDGL Share HeldPrevious Price per MDGL Share Held
2025-09-26 (Friday)2,975USD 1,262,084USD 1,262,084
2025-09-25 (Thursday)2,975USD 1,258,395MDGL holding decreased by -11454USD 1,258,3950USD -11,454 USD 422.99 USD 426.84
2025-09-24 (Wednesday)2,975USD 1,269,849USD 1,269,849
2025-09-17 (Wednesday)2,957USD 1,234,341MDGL holding decreased by -28446USD 1,234,3410USD -28,446 USD 417.43 USD 427.05
2025-09-16 (Tuesday)2,957USD 1,262,787USD 1,262,787
2025-09-12 (Friday)2,939USD 1,270,295USD 1,270,295
2025-09-11 (Thursday)2,939USD 1,291,544USD 1,291,544
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MDGL by Blackrock for IE00B3VWM098

Show aggregate share trades of MDGL

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-7 407.090* 309.93 Profit of 2,170 on sale
2025-07-31BUY21 302.510* 309.48
2025-06-30SELL-14 302.640* 309.52 Profit of 4,333 on sale
2025-06-25SELL-7 277.640* 309.88 Profit of 2,169 on sale
2025-06-20SELL-14 285.730* 310.42 Profit of 4,346 on sale
2025-05-30BUY682 275.260* 313.72
2025-05-23BUY5 267.560* 315.56
2025-05-19SELL-5 290.720* 316.67 Profit of 1,583 on sale
2025-05-15SELL-15 291.820* 317.11 Profit of 4,757 on sale
2025-05-12SELL-5 300.760* 317.76 Profit of 1,589 on sale
2025-05-09SELL-5 294.640* 317.97 Profit of 1,590 on sale
2025-04-30SELL-5 333.910* 318.45 Profit of 1,592 on sale
2025-04-24SELL-10 319.930* 317.99 Profit of 3,180 on sale
2025-04-17SELL-5 301.660* 318.84 Profit of 1,594 on sale
2025-04-15SELL-15 321.100* 318.94 Profit of 4,784 on sale
2025-04-14SELL-15 322.320* 318.90 Profit of 4,784 on sale
2025-04-09SELL-20 313.950* 319.11 Profit of 6,382 on sale
2025-04-07SELL-35 310.520* 319.40 Profit of 11,179 on sale
2025-04-04SELL-50 314.390* 319.46 Profit of 15,973 on sale
2025-03-31BUY5 331.230* 319.08
2025-03-19SELL-10 340.770* 317.00 Profit of 3,170 on sale
2025-03-14SELL-30 348.350* 315.90 Profit of 9,477 on sale
2025-03-13SELL-10 323.020* 315.80 Profit of 3,158 on sale
2025-03-12SELL-170 327.310* 315.63 Profit of 53,657 on sale
2025-03-07SELL-10 331.410* 314.89 Profit of 3,149 on sale
2025-03-06SELL-15 328.770* 314.67 Profit of 4,720 on sale
2025-03-03SELL-5 313.470* 314.06 Profit of 1,570 on sale
2025-02-28BUY337 341.270* 313.61
2025-02-26SELL-4 355.880* 312.52 Profit of 1,250 on sale
2025-02-25SELL-12 309.490* 312.57 Profit of 3,751 on sale
2025-02-18BUY20 339.870* 310.12
2025-02-13BUY4 351.710* 308.21
2025-02-12BUY4 340.170* 307.55
2025-02-11BUY12 331.790* 307.05
2025-02-06BUY36 330.270* 305.28
2025-01-27BUY4 310.920* 300.31
2024-12-30BUY20 311.620* 297.51
2024-12-06BUY16 320.840* 295.53
2024-12-05BUY4 313.050* 294.93
2024-12-04BUY20 318.480* 294.08
2024-11-29BUY20 328.190* 290.65
2024-11-27BUY16 331.450* 287.10
2024-11-26BUY4 336.740* 284.85
2024-11-21BUY20 329.240* 276.04
2024-11-20BUY12 317.090* 273.76
2024-11-18BUY48 303.490* 269.37
2024-11-12BUY32 339.040* 264.73
2024-11-08BUY20 350.700* 258.59
2024-11-07BUY60 354.850* 251.19
2024-11-06BUY8 338.220* 243.93
2024-10-31BUY4 259.340* 209.92
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MDGL

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1947,045091,14051.6%
2025-09-1897,59520142,26468.6%
2025-09-1742,376098,93142.8%
2025-09-1636,679065,32356.2%
2025-09-1548,3091,38289,38354.0%
2025-09-1227,868066,49141.9%
2025-09-1135,091887,94839.9%
2025-09-1042,4850107,39439.6%
2025-09-0947,5976138,64734.3%
2025-09-08283,8573,995334,49484.9%
2025-09-0549,7832,100120,35841.4%
2025-09-0442,4951,23592,06146.2%
2025-09-0375,350249148,25350.8%
2025-09-02101,5130187,52454.1%
2025-08-2952,376100114,35545.8%
2025-08-2854,862800124,33644.1%
2025-08-2778,5760148,94552.8%
2025-08-2657,9040124,86946.4%
2025-08-2550,37010395,26152.9%
2025-08-22110,8791,848187,03159.3%
2025-08-21130,9242,837216,68360.4%
2025-08-2070,0902,873137,72750.9%
2025-08-19119,3640209,09157.1%
2025-08-18237,9031,300399,19259.6%
2025-08-1549,0942,88280,97360.6%
2025-08-1477,46229130,47659.4%
2025-08-13145,2473,549248,83258.4%
2025-08-1298,7201,400172,44857.2%
2025-08-1156,8190103,42654.9%
2025-08-08108,1891,125175,93161.5%
2025-08-0799,632100161,14761.8%
2025-08-0672,4481114,64463.2%
2025-08-05363,796372508,27371.6%
2025-08-04113,59528143,88079.0%
2025-08-0153,528783,20164.3%
2025-07-31157,77414224,32970.3%
2025-07-30146,3481206,63870.8%
2025-07-2978,601169118,74266.2%
2025-07-2869,568789106,07865.6%
2025-07-2553,06284106,59749.8%
2025-07-2460,93971105,41057.8%
2025-07-2362,2102148,70641.8%
2025-07-22131,037243192,02768.2%
2025-07-2126,5021343,68860.7%
2025-07-1894,965459136,91969.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.